Revvity Inc (BSP:R1VT34)
R$ 23.77 0 (0%) Market Cap: 81.00 Bil Enterprise Value: 93.46 Bil PE Ratio: 56.19 PB Ratio: 1.79 GF Score: 65/100

PerkinElmer Inc at JPMorgan Healthcare Conference Transcript

Jan 11, 2022 / 04:15PM GMT
Release Date Price: R$39.55
Rachel Marie Vatnsdal Olson
JPMorgan Chase & Co, Research Division - Analyst

Good morning, everyone. This is Rachel Vatnsdal from our life science tools and diagnostics team here at JPMorgan. It's my pleasure to introduce our next company, PerkinElmer. And as a reminder, if you have any questions, please submit them through the Q&A function on our conference website.

And with that, I will turn it over to Prahlad.

Prahlad R. Singh
PerkinElmer, Inc. - CEO, President & Director

Welcome, everyone. Thank you, JPMorgan, for the opportunity to provide an update on the progress we've been making on the transformation of the business. While in 2019 and 2020, we really started to transform the business internally. Looking back, I think 2021 will be marked as a year that we were able to really accelerate our shift into faster-growing markets, which will continue to benefit the company in the years to come.

Before we start, please read the safe harbor statement and consult our website for additional disclosures regarding any forward

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot